Related Experiment Video

Updated: Dec 17, 2025

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

1.9K

Updates on Receptors Targeted by Heterocyclic Scaffolds: New Horizon in Anticancer Drug Development

Rajeev Kharb1

  • 1Centre for Pharmaceutical Chemistry & Pharmaceutical Analysis, Amity Institute of Pharmacy, Amity University Uttar Pradesh, Noida-201313, Uttar Pradesh, India.

Anti-Cancer Agents in Medicinal Chemistry
|June 21, 2020
PubMed

Insights

Conventional anticancer drugs show limited efficacy and severe side effects. This study explores novel heterocyclic compounds as targeted anticancer agents, aiming for improved efficacy and safety in cancer treatment.

Area of Science:

  • Oncology
  • Medicinal Chemistry
  • Drug Discovery

Background:

  • Cancer remains a leading global cause of death, with conventional treatments often proving inefficient and causing significant side effects.
  • Existing anticancer drugs like methotrexate and cisplatin have limitations in efficacy and tolerability, necessitating the development of improved therapeutic strategies.
  • Numerous cancer-related receptors (e.g., tyrosine kinase, histone deacetylase) have been identified as potential therapeutic targets for novel anticancer agents.

Purpose of the Study:

  • To review and identify heterocyclic compounds with potential anticancer activity from recent scientific literature.
  • To explore the ability of these heterocyclic compounds to effectively bind with cancer-related receptors.
  • To provide insights for the design and development of safer and more effective targeted anticancer drugs.

Main Methods:

  • Literature review of recent scientific publications focusing on heterocyclic compounds and their anticancer properties.
  • Analysis of identified heterocyclic compounds for their potential to interact with specific cancer-related molecular targets.
  • Evaluation of pharmacological activities and safety profiles of promising heterocyclic drug candidates.

Main Results:

  • Heterocyclic compounds, including oxadiazole, thiazole, and benzimidazole derivatives, exhibit significant anticancer potential.
  • These heterocycles demonstrate broad-spectrum pharmacological activities, including potent anticancer effects.
  • The review highlights specific heterocyclic structures capable of effective binding to key cancer-related receptors.

Conclusions:

  • Heterocyclic compounds represent a promising class of molecules for developing novel anticancer therapeutics.
  • Targeting cancer-related receptors with specifically designed heterocyclic compounds can enhance treatment efficacy and improve safety profiles.
  • This research provides a foundation for future drug design and development in the field of oncology, aiming for more effective cancer therapies.
Keywords:
Anticancerdrug designheterocyclesreceptorstherapy failure.tubulin inhibitors

More Related Videos

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

4.2K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.5K